ValuEngine Downgrades Denali Therapeutics (NASDAQ:DNLI) to Hold

Share on StockTwits

Denali Therapeutics (NASDAQ:DNLI) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Monday, ValuEngine reports.

Several other equities research analysts have also weighed in on DNLI. Nomura assumed coverage on Denali Therapeutics in a research report on Friday, September 13th. They issued a “buy” rating and a $35.00 target price on the stock. Wedbush assumed coverage on Denali Therapeutics in a research report on Wednesday, September 25th. They issued a “neutral” rating and a $19.00 target price on the stock. They noted that the move was a valuation call. Zacks Investment Research raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 27th. Morgan Stanley set a $32.00 target price on Denali Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, BTIG Research assumed coverage on Denali Therapeutics in a research report on Friday, August 9th. They issued a “buy” rating and a $30.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $27.25.

Shares of DNLI stock traded up $0.81 on Monday, hitting $15.21. 915,616 shares of the stock traded hands, compared to its average volume of 352,026. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.65 and a quick ratio of 10.66. The company has a market capitalization of $1.38 billion, a PE ratio of -39.00 and a beta of 2.15. Denali Therapeutics has a 1-year low of $13.78 and a 1-year high of $28.86. The company’s fifty day moving average is $16.68 and its 200 day moving average is $20.12.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.15). The firm had revenue of $4.20 million for the quarter, compared to analyst estimates of $4.52 million. Denali Therapeutics had a negative net margin of 40.78% and a negative return on equity of 11.03%. As a group, equities research analysts expect that Denali Therapeutics will post -2.12 EPS for the current year.

In other news, COO Alexander O. Schuth sold 7,500 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $18.81, for a total value of $141,075.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Ryan J. Watts sold 8,581 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $18.05, for a total value of $154,887.05. Following the completion of the transaction, the chief executive officer now directly owns 12,505 shares of the company’s stock, valued at approximately $225,715.25. The disclosure for this sale can be found here. Insiders sold 23,581 shares of company stock worth $432,162 over the last ninety days. 21.20% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC grew its stake in shares of Denali Therapeutics by 7.9% in the second quarter. Virtus ETF Advisers LLC now owns 14,246 shares of the company’s stock worth $296,000 after purchasing an additional 1,045 shares in the last quarter. TD Asset Management Inc. grew its stake in shares of Denali Therapeutics by 4.7% in the second quarter. TD Asset Management Inc. now owns 24,500 shares of the company’s stock worth $509,000 after purchasing an additional 1,100 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Denali Therapeutics by 19.0% in the second quarter. JPMorgan Chase & Co. now owns 13,170 shares of the company’s stock worth $271,000 after purchasing an additional 2,101 shares in the last quarter. Swiss National Bank grew its stake in shares of Denali Therapeutics by 2.0% in the second quarter. Swiss National Bank now owns 114,800 shares of the company’s stock worth $2,383,000 after purchasing an additional 2,300 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its stake in shares of Denali Therapeutics by 19.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 20,555 shares of the company’s stock worth $427,000 after purchasing an additional 3,330 shares in the last quarter. 73.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Further Reading: What does an outperform rating mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.